RaySearch Laboratories AB (CHIX:RAYBS) Moat Score: 6/10 (As of Jul. 07, 2026)


CHIX:RAYBS RaySearch Laboratories AB CHIX:RAYBS
95 GF Score
Price kr215.50
GF Value kr180.42
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB Moat Score?

RaySearch Laboratories AB CHIX:RAYBS 95 Moat Score is 6 as of Jul. 07, 2026. GuruFocus rates CHIX:RAYBS with a GF Score™ of 95/100 and a GF Value™ of kr180.42 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 676 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 99.11% on this metric.

RaySearch Laboratories AB has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

RaySearch Laboratories AB has Narrow Moat: RaySearch Laboratories AB has a strong narrow moat due to its valuable intellectual property in radiation therapy software and consistent innovation. However, it faces competition from larger players, limiting its moat to narrow.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes RaySearch Laboratories AB might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

RaySearch Laboratories AB  (CHIX:RAYBs) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

RaySearch Laboratories AB Moat Score Related Terms

CHIX:RAYBS vs VEEV, BTSG, TEM: Moat Score Comparison

For the Health Information Services subindustry, RaySearch Laboratories AB's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RaySearch Laboratories AB Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Moat Score distribution charts can be found below:

* The bar in red indicates where RaySearch Laboratories AB's Moat Score falls into.


CHIX:RAYBS
95GF Score
RaySearch Laboratories AB CHIX:RAYBS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
RaySearch Laboratories AB (CHIX:RAYBS) has a Moat Score of 6 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, RaySearch Laboratories AB ranks #6 out of 676 companies in the Healthcare Providers & Services industry, placing it in the top 0.90000000000001%.
Is RaySearch Laboratories AB's Moat Score too high?
RaySearch Laboratories AB's current Moat Score is 6. Based on the distribution chart, RaySearch Laboratories AB ranks #6 out of 676 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Moat Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #6 out of 676 companies for Moat Score. This places RaySearch Laboratories AB in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. RaySearch Laboratories AB's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr180.42, compared to a current price of kr215.50 — trading 19.4% above its estimated fair value. The current Moat Score is 6. RaySearch Laboratories AB's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Moat Score is 6 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued. The current stock price of kr215.50 is trading 19.4% above its estimated GF Value™ of kr180.42. GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.

Key valuation signals for CHIX:RAYBS:

  • Moat Score: 6
  • GF Value™: kr180.42 vs. price of kr215.50 (19.4% above fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
95GF Score

Get the complete analysis for CHIX:RAYBS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr215.50
Price
kr180.42
GF Value